16 Feb Acquisitions Anonymous: Genotypnig mice at 55% EBITDA
In this episode of Acquisitions Anonymous, Michael and Heather discuss an investment opportunity in a genomic testing , specializing in DNA sequencing and genotyping for mice. Despite their initial unfamiliarity with the technical details, they recognize the company’s significant role in pharmaceutical research. They are impressed by its financial performance, noting substantial growth in revenue and EBITDA, along with high margins. The conversation also explores potential barriers to entry, the impact of technological advancements, and the type of buyer suitable for such a specialized business. They conclude that the company’s high margins, growth potential, and strategic importance in healthcare and pharmaceuticals make it an attractive investment opportunity, albeit one requiring a buyer to quickly grasp the complexities of the field.
